ATEC

Business Context and Reporting Period

Company: Alphatec Holdings, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: Alphatec is a medical technology company focused on the design, development, manufacturing, and marketing of products for the surgical treatment of spine disorders, with a specific emphasis on the aging spine. The company operates through wholly-owned subsidiaries Alphatec Spine, Inc. and Scient'x S.A.S. (acquired March 26, 2010).
Key Strategy: The company aims to be the world's leading independent full-line spine company by leveraging a "surgeons' culture" for product development, expanding international operations (particularly in Europe and Asia via Scient'x), and focusing on minimally invasive techniques and biologics.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 42.3% to $171.6 million, driven primarily by the acquisition of Scient'x (contributing $29.0 million in sales) and organic growth in U.S. ($10.1 million), Europe ($9.4 million), and Asia ($2.6 million) channels.
• Acquisition Impact: The March 2010 acquisition of Scient'x significantly expanded the company's international footprint and product portfolio. Pro forma results indicate the combined entity would have generated $182.9 million in revenue for 2010.
• Expense Increases: Operating expenses rose to $124.6 million (from $91.2 million in 2009). Key drivers included:
  • Sales & Marketing: Increased 34.7% due to expanded European activities and higher commissions.
  • General & Administrative: Increased 60.8% due to integration costs, regulatory expenses, and the absence of one-time benefits recognized in 2009.
  • Transaction & Restructuring: $3.7 million in transaction costs and $2.4 million in restructuring expenses related to the Scient'x acquisition.
• Debt Restructuring: In October 2010, the company amended its credit facility with Silicon Valley Bank (SVB), removing Oxford Finance as a co-lender. The facility was converted to a $32 million working capital line of credit, with $31.9 million drawn as of year-end.

Guidance, Outlook, Risks, and Contingencies

• Liquidity Outlook: Management believes current cash ($23.2 million) and accounts receivable ($39.8 million) are sufficient to fund operations through December 31, 2011. However, this is contingent on achieving planned revenue growth to meet credit facility covenants.
• Credit Facility Covenants: The company must maintain a minimum adjusted quick ratio and minimum quarterly free cash flow. Failure to meet these covenants could result in the loan being declared immediately due and payable.
• Regulatory Risks:
  • FDA Warning Letter: The company received an FDA Warning Letter in June 2010 regarding quality system non-conformances. A re-inspection occurred in December 2010; results were pending at the time of filing. A subsequent Warning Letter in January 2011 regarding post-market surveillance was also noted.
  • Product Approvals: Several key products (e.g., OsseoFix, OsseoScrew) are awaiting FDA 510(k) clearance or are in clinical trials. Delays could hinder commercialization.
• Legal Proceedings:
  • Patent Litigation: Cross Medical Products, LLC sued for alleged breach of a patent license agreement regarding polyaxial pedicle screws. In February 2011, the court granted partial summary judgment to Cross on contract interpretation, though the case is not dispositive. Alphatec also sued Biomet, Inc. for patent infringement.
  • Securities Litigation: A securities class action and shareholder derivative suits were filed alleging false statements regarding the Scient'x acquisition and financial guidance.
  • False Claims Act: A qui tam complaint regarding Scient'x USA was dismissed without prejudice, but the Department of Justice continues its review.
• Healthcare Reform: The Patient Protection and Affordable Care Act (PPACA) imposes a 2.3% excise tax on domestic medical device sales effective 2013 and introduces payment reforms that could reduce reimbursement rates.

Investor Verification Checklist

• Covenant Compliance: Verify the company's ability to meet the minimum adjusted quick ratio and free cash flow covenants under the SVB credit facility in upcoming quarters.
• FDA Status: Confirm the outcome of the FDA re-inspection and the status of pending 510(k) applications for OsseoFix and OsseoScrew.
• Legal Exposure: Monitor the progress of the Cross Medical Products patent litigation and the DOJ review of the Scient'x USA False Claims Act allegations.
• Integration Synergies: Assess whether the anticipated cost savings and revenue synergies from the Scient'x acquisition are being realized as projected.
• Inventory Levels: Review inventory turnover and reserves, as inventory increased by $14.7 million in 2010 to support higher sales volumes, creating potential obsolescence risk if demand slows.